Morningstars fair value estimat for Novozymes er 243 DKK pr. aktie Estimatet er primært drevet af forventninger om gennemsnitlig vækst på 9 pct. i omsætningen over de næste fem år, og en mindre forbedring af indtjeningsmarginalerne. Baseret på Novozymes’ aktuelle kurs på 255 DKK pr. aktie er det vores vurdering, at aktiekursen allerede mere end rigeligt afspejler markedets lovende forventninger til selskabets fortsatte vækst.
Hele Morningstars analyse af Novozymes kan læses her.
©2014 Morningstar. All rights reserved. The information, data, analyses, and opinions contained herein (1) are proprietary to Morningstar, Inc. and its affiliates (collectively, “Morningstar”), (2) may not be copied or redistributed, (3) do not constitute investment advice offered by Morningstar (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (5) are not warranted to be accurate, complete, or timely. Certain information may be self-reported by the investment vehicle and not subject to independent verification. Morningstar shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses or opinions or their use. Past performance is no guarantee of future results.